-
Mashup Score: 0
Patients with high-risk early-stage non-small cell lung cancer who underwent surgery reported similar quality of life outcomes as those who had radiation.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 2Identifying EGFR-Mutant Lung Cancer Patients Who Will Benefit From Immune Checkpoint Inhibitors - 7 day(s) ago
Real-world data suggest that lung cancer patients with uncommon EGFR mutations may benefit from treatment with immune checkpoint inhibitors.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Cancer of the Lung and Bronchus - Cancer Stat Facts - 11 day(s) ago
Lung and Bronchus Cancer statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Cancer of the Lung and Bronchus - Cancer Stat Facts - 25 day(s) ago
Lung and Bronchus Cancer statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study - 1 month(s) ago
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-mutated NSCLC that progressed before TKI therapy. MATERIALS AND METHODS We compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). RESULTS A total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - 1 month(s) ago
Treatment with repotrectinib shrank tumors in a substantial number of people with advanced NSCLC with ROS1 fusions, results of the TRIDENT-1 trial show.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Dr Leal on the Utility of Patritumab Deruxtecan in EGFR+ NSCLC - 1 month(s) ago
Ticiana Leal, MD, discusses the investigation of patritumab deruxtecan in the HERTHENA-Lung01 study in advanced EGFR-mutated non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Emerging Targets in Non–Small Cell Lung Cancer - 2 month(s) ago
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Patients with high-risk early-stage #LungCancer had similar quality of life results when they received either surgery via sublobar resection or radiation via SBRT after one year. #LCSM Read more here: https://t.co/Ln5VXWcUbU